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Introduction:  The  Portuguese  National  Registry  of  Transcatheter  Aortic  Valve  Implantation
records prospectively  the  characteristics  and  outcomes  of  transcatheter  aortic  valve  implanta-
tion (TAVI)  procedures  in  Portugal.
Objectives:  To  assess  the  30-day  and  one-year  outcomes  of  TAVI  procedures  in  Portugal.
Methods:  We  compared  TAVI  results  according  to  the  principal  access  used  (transfemoral  (TF)
vs. non-transfemoral  (non-TF)).  Cumulative  survival  curves  according  to  access  route,  other
iables  were  obtained.  The  Valve  Academic  Research  Consortium-
oint  of  early  (30-days)  safety  was  assessed.  VARC-2  predictors  of
e  mortality  were  identified.procedural  and  clinical  var
2 (VARC-2)  composite  endp
30-days and  1-year  all-caus∗ Corresponding author.
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Results:  Between  January  2007  and  December  2018,  2346  consecutive  patients  underwent  TAVI
(2242 native,  104  valve-in-valve;  mean  age  81±7  years,  53.2%  female,  EuroSCORE-II  -  EuroS-II,
4.3%). Device  success  was  90.1%  and  numerically  lower  for  non-TF  (87.0%).  Thirty-day  all-cause
mortality was  4.8%,  with  the  TF  route  rendering  a  lower  mortality  rate  (4.3%  vs.  10.1%,  p=0.001)
and higher  safety  endpoint  (86.4%  vs.  72.6%,  p<0.001).  The  one-year  all-cause  mortality  rate  was
11.4%, and  was  significantly  lower  for  TF  patients  (10.5%  vs.  19.4%,  p<0.002).  After  multivariate
analysis, peripheral  artery  disease,  previous  percutaneous  coronary  intervention,  left  ventricu-
lar dysfunction  and  NYHA  class  III-IV  were  independent  predictors  of  30-day  all-cause  mortality.
At one-year  follow-up,  NYHA  class  III-IV,  non-TF  route  and  occurrence  of  life-threatening  blee-
ding predicted  mortality.  Kaplan-Meier  survival  analysis  of  the  first  year  of  follow-up  shows
decreased  survival  for  patients  with  an  EuroS-II>5%  (p<0.001)  and  who  underwent  non-TF  TAVI
(p<0.001).
Conclusion:  Data  from  our  national  real-world  registry  showed  that  TAVI  was  safe  and  effective.
The use  of  a  non-transfemoral  approach  demonstrated  safety  in  the  short  term.  Long-term  pro-
gnosis was,  however,  adversely  associated  with  this  route,  with  comorbidities  and  the  baseline
clinical status.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an







Impacto  clínico  em  curto  e  longo  prazo  da  Válvula  Aórtica  Percutânea  (VAP)  em
Portugal  de  acordo  com  diferentes  acessos  --  Dados  do  Registo  Nacional  de
Cardiologia  de  Intervenção  de  VAP
Resumo
Introdução:  O  Registo  Nacional  de  Cardiologia  de  Intervenção  de  Válvulas  Aórticas  Percutâneas
(RNCI-VaP)  documenta  prospetivamente  as  características  e  resultados  da  VAP  em  Portugal.
Objetivos:  Avaliar  os  resultados  a  30  dias  e  um  ano  da  VAP  em  Portugal.
Métodos:  Comparação  dos  resultados  da  VAP  de  acordo  com  o  acesso  (transfemoral  --  TF  versus
não transfemoral  --  não  TF).  Obtiveram-se  curvas  de  sobrevivência  cumulativa  de  acordo  com
o acesso,  variáveis  do  procedimento  e  clínicas.  Avaliou-se  a  segurança precoce  (30  dias)  do
procedimento,  de  acordo  com  os  critérios  Valve  Academic  Research  Consortium-2  (VARC-2).
Identificaram-se  preditores  de  mortalidade  a  30  dias  e  um  ano.
Resultados:  Entre  janeiro  2007  e  dezembro  2018,  realizaram-se  2346  VAP  (2242  nativas,  104
Valve-in-Valve  [VIV];  idade  média  81±7  anos,  53,2%  mulheres,  EuroSCORE-II  [EuroS-II]  4,3%).
Sucesso do  dispositivo  foi  obtido  em  90,1%,  inferior  para  o  não  TF  (87,0%).  Aos  30  dias,  a
mortalidade  global  foi  de  4,8%,  apresentando  o  TF  menor  mortalidade  (4,3%  versus  10,1%,
p=0,001) e  maior  segurança (86,4%  versus  72,6%,  p<0,001).  A  mortalidade  a  um  ano  foi  11,4%,
significativamente  menor  para  o  TF  (10,5%  versus  19,4%,  p<0,002).  Após  análise  multivariável,
identificaram-se  como  preditores  de  mortalidade  a  30  dias  doença  arterial  periférica,  angio-
plastia prévia,  disfunção  ventricular  esquerda  e  classe  NYHA  III-IV.  A  um  ano,  NYHA  III-IV,  o
acesso não  TF  e  a  hemorragia  com  risco  de  vida  foram  preditores  de  mortalidade.  A  análise  de
sobrevivência  a  um  ano  evidenciou  menor  sobrevivência  para  EuroS-II>5%  (p<0,001)  e  VAP  não
TF (p<0,001).
Conclusões:  Dados  do  RNCI-VaP  mostram  que  a  VAP  foi  segura  e  eficaz.  O  acesso  não  TF  mostrou
segurança em  curto  prazo.  O  prognóstico  em  longo  prazo  foi  influenciado  negativamente  por
este acesso,  assim  como  comorbilidades  e  o  estado  clínico  de  base  do  doente.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é um








ntroductionevere  aortic  stenosis  (AS)  is  the  most  prevalent  type  of
alvular  heart  disease  in  the  western  world,1 with  particu-




hows  a  pattern  of  an  aging  population  and  since  1960  life
xpectancy  at  birth  in  Portugal  has  increased  from  64  to  82
ears.  This  will  increase  the  burden  of  AS  and  the  need  to
reat  it.3,4 Surgical  aortic  valve  (SAV)  replacement  is  an  esta-

















































procedural  mortality  (all-cause  mortality  within  30  days  or
during  index  procedure  hospitalization  if  the  postopera-
tive  length  of  stay  was  longer  than  30  days);  iii)  early  (30Short  and  long-term  clinical  impact  of  transcatheter  aortic  
in  the  last  decade,  transcatheter  aortic  valve  implanta-
tion  (TAVI)  has  emerged  as  a  minimally  invasive  treatment
for  AS,  initially  for  inoperable  and  high  risk  patients6 but
increasingly,  as  evidence  grows,  it  is  used  in  lower  risk
patients.7,8 Evidence  is  building  on  the  durability  of  trans-
catheter  aortic  valves,  with  over  90%  of  patients  remaining
free  of  structural  valve  dysfunction  between  five  and  10
years  post-implantation.9 This  may  encourage  increased
use  of  this  technology  in  younger  and  lower  risk  patients.
Growing  experience,  solid  evidence,  refined  pre-procedural
assessment  with  multi-slice  computed-tomography  (MSCT)
and  new  generation  transcatheter  devices  are  causing  a
shift  toward  new  indications,  including  lower-surgical  risk
patients.10,11
Transfemoral  (TF)  access  is  the  preferred  route,  since
it  is  less  invasive,  and  patient  recovery  is  faster,  involving
shorter  hospital  stays.12 Nevertheless,  up  to  one  third  of  eli-
gible  patients  may  not  be  appropriate  candidates  for  a  TF
approach  because  of  major  peripheral  artery  disease  (PAD).
Other  routes  have  emerged  as  alternatives,  but  are  associa-
ted  with  worse  outcomes,  particularly  when  considering  the
transapical  (TA)  route.13
Another  field  of  increasing  importance  in  TAVI  is  prost-
hetic  valve  dysfunction  (PVD).  Currently,  patients  with
previously  implanted  biological  SAV  can  be  treated  with  a
valve-in-valve  (ViV)  procedure  for  PVD,  which  has  been  asso-
ciated  with  good  one-year  outcomes.14
Registries  have  reported  the  results  of  TAVI  in  several
countries,  showing  consistently  high  implantation  success
rates;  a  recent  meta-analysis  reported  an  overall  European
30-day  mortality  of  8%,  however  with  substantial  differences
among  registries.15,16 Mid-  and  long-term  follow-up  results
show  survival  rates  over  80%  at  one  year,  with  persistent
improvement  of  clinical  status.17
The  Portuguese  National  Registry  of  Transcatheter  Aortic
Valve  Implantation  (RNCI-VaP)  is  a  national  registry  con-
ducted  with  the  main  purpose  of  assessing  all  comers  with
aortic  valve  disease  or  aortic  valve  prosthesis  dysfunction
that  undergo  TAVI  in  Portugal,  ensuring  comprehensive  cove-
rage  in  Portugal.18 The  main  goals  of  the  registry  are  to
document  in  a  prospective  and  consecutive  fashion  the  cha-
racteristics  of  patients  who  undergo  TAVI,  ascertain  the
results  of  these  treatments  in  Portugal,  develop  scienti-
fic  work  based  on  data  included  in  the  registry,  establish
treatment  recommendations  regarding  TAVI  procedures  and
collaborate  with  other  similar  international  registries.  A
position  paper  statement  from  the  Portuguese  Association
of  Cardiovascular  Intervention  (APIC)  has  already  underli-
ned  the  importance  of  a  systematic  assessment  and  report
of  patients  who  undergo  TAVI  in  Portugal.19 The  members
of  this  committee  are  all  interventional  cardiologists.  It  is
divided  into  an  executive  board  of  three  members  which
includes  the  Registry  Coordinator  and  the  scientific  board.
There  is  no  specific  funding  for  this  registry  which  has
been  completely  developed,  maintained  and  sponsored  by
APIC.
This  article  is  the  first  report  of  real-world  clinical  data
from  the  RNCI-VaP  registry.  It  aims  to  identify  patient  and
procedure  characteristics  and  evaluate  30-day  and  one-year
outcomes  of  TAVI  in  Portugal.
d
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ethods
atient  selection
he  RNCI-VaP  is  a  continuous,  observational  and  prospective
egistry,  which  began  in  2007.  A  total  of  14  exclusively  Portu-
uese  private  and  public  centers  participated  in  the  registry
n  a  voluntary  basis.  Registry  data  inclusion  and  analysis  are
he  exclusive  responsibility  of  the  members  of  the  RNCI-VaP,
hich  is  free  from  industry  body  influence.  The  registry  com-
lies  with  Portuguese  data  protection  laws  and  was  approved
y  a  central  ethics  board.  All  patients  gave  written  informed
onsent.
Selection  of  symptomatic  patients  with  severe  AS  or  PVD
or  TAVI  followed  a  multidisciplinary  approach  in  which  all
ndividual  cases  were  discussed  within  a  heart  team  and
he  procedures  performed  in  hospitals  with  on-site  car-
iac  surgery.20 Patients  were  included  if  considered  high
isk  for  traditional  aortic  valve  replacement  (AVR)  surgery
r  deemed  inoperable.  Patients  were  excluded  if  their  life
xpectancy  with  TAVI  was  ≤1  year  or  the  patient’s  quality
f  life  was  unlikely  to  improve  with  TAVI.  MSCT  was  rou-
inely  performed  to  select  the  access  route,  and  aspects
uch  as  size,  tortuosity  and  calcification  were  assessed.  If  a
emoral  approach  was  not  possible,  an  alternative  access
as  planned  (transcarotid,  transaortic,  transubclavian  or
ransapical).  MSCT  data  also  enabled  characterization  of
he  aortic  annulus  and  valve,  sinus  of  Valsalva,  coronary
stia  and  ascending  aorta.  The  decision  regarding  the  access
oute,  the  prosthesis  type  and  size  were  made  according  to
ach  center’s  routine,  taking  into  consideration  the  clini-
al  and  morphological  assessment.  At  all  TAVI  centers,  the
rocedure  was  performed  with  the  support  of  at  least  one
nesthesiologist.
ata  acquisition  and  quality  control
ata  were  entered  into  a  dedicated  database  and  sent  to
he  National  Cardiology  Data  Collection  Center  of  the  Por-
uguese  Society  of  Cardiology.  Events  and  values  collected
re  site  reported,  and  there  are  no  core  laboratories.  Data
ere  examined  and  validated,  and  the  participating  cen-
ers  contacted  in  the  event  of  any  queries  or  discrepancies.
upervision  of  the  RNCI-VaP  is  the  responsibility  of  the
rincipal  investigators  (A.L.,  A.F.,  B.S.,  E.I.O.,  E.J.,  F.S.,
.S.,  J.S.M.,  L.R.,  R.C.,  S.B.)  and  the  registry  coordinator
R.C.T.).
tudy  variables  and  outcomes
tudy  variables  were  based  on  the  recommendations  of  the
pdated  VARC-2  consensus  document.21 They  included  the
ollowing  in-hospital  and  30-days  outcomes:  i)  immediate
rocedural  mortality  (up  to  72  hours  post-procedure);  ii)ays)  safety  (defined  as  freedom  from  all-cause  mortality,  all
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Figure  1  Evolution  in  the  number  of  transcatheter  aortic  valve  implantation  (TAVI)  procedures  in  Portugal  since  the  beginning  of

















































he Portuguese  Registry  of  TAVI  in  2007  until  the  end  of  2018  (da
rocedures; n=2346  TAVI  procedures  in  the  registry).
troke,  life-threatening  bleeding,  acute  kidney  injury  stage
 or  3,  coronary  artery  obstruction  requiring  intervention,
ajor  vascular  complication  and  valve-related  dysfunction
equiring  a  repeat  procedure);  iv)  myocardial  infarction;
)  stroke  and  transient  ischemic  attack  (TIA);  vi)  bleeding
omplications  (defined  by  the  Bleeding  Academic  Research
onsortium  criteria);  vii)  acute  kidney  injury  (acute  kidney
njury  network  classification);  viii)  vascular  complications;
x)  other  TAVI-related  complications.  All-cause  mortality  was
ssessed  at  30  days  and  at  one-year  follow-up.  Prospective
ollow-up  of  adverse  events  was  reported  by  the  investi-
ators.  At  30-days  and  one-year,  48  (2%)  and  530  (22%)
atients,  respectively,  were  lost  to  follow-up.
evice  description
he  national  registry  is  open  to  any  type  of  commercial
evice.  To  date,  12  different  valves  and  their  iterations
ave  been  used  including:  Medtronic  CoreValveTM, Edwards
apienTM,  Abbott  PorticoTM,  Boston  Scientific  Acurate  neoTM
nd  Lotus  EdgeTM,  Direct  Flow  MedicalTM,  NVT  Allegra  TAVI
ystem  TFTM,  and  Medtronic  EngagerTM.  The  technical  speci-
cations  of  these  devices  have  been  described  elsewhere.22
tatistical  analysisistribution  of  continuous  variables  was  determined  using
he  Shapiro-Wilk  test  and  they  are  expressed  as  mean  ±  SD  or
s  median  ±  IQR,  where  appropriate.  Categorical  variables





resented  in  number  of  procedures  per  year;  n=2380  global  TAVI
ariables  were  compared  using  the  unpaired  Student’s  t test
r  the  Wilcoxon  rank-sum  test,  as  appropriate.  Chi-square
est  or  Fisher  exact  test  was  used  to  compare  categorical
ariables.
Multivariate  analysis  for  the  prediction  of  all-cause  mor-
ality  during  30-days  and  one-year  follow-up  was  performed
sing  Cox  regression,  by  including  all  statistically  significant
ariables  in  the  univariate  analysis  and  those  considered  cli-
ically  relevant.  The  results  are  expressed  as  hazard  ratios
HR)  and  95%  confidence  intervals  (CI  95%).  Survival  curves
ere  obtained  with  the  Kaplan-Meier  method.  A  log-rank
est  was  used  to  compare  survival  between  groups  during
ollow-up.
A  p  value  <0.05  was  considered  statistically  significant.
ll  analyses  were  performed  using  SPSS  statistics  software
version  23.0,  SPSS,  Inc.,  Chicago,  IL).
esults
tudy  population
atient  population  and  procedural  characteristics.  From
anuary  2007  to  December  2018,  a  total  of  2346  consecutive
atients  were  included  in  the  Portuguese  National  Regis-
ry  of  TAVI,  with  no  exclusion  criteria.  In  the  last  10  years,
here  has  been  an  exponential  increase  in  the  number  of
rocedures  performed,  with  a  slight  deceleration  in  2018,
s  illustrated  in  Figure  1. The  baseline  characteristics  of  the
opulation  are  shown  in  Table  1.  The  mean  age  of  our  global
ohort  was  81±7  years  with  the  youngest  and  oldest  patients
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Table  1  Baseline  characteristics  of  the  study  population  and  according  to  the  transcatheter  aortic  valve  implantation  access
route.a
Variable  All  (n=2346)  TF  (n=2131)  Non-TF  (n=214)  p  value  (TF  vs.  non-TF)
Age,  years  81.1±7.1  (20-96)  81.3±7.1  79.2±7.0  <0.001
Female 53.2  (1246/2341)  54.5  (1159/2127)  40.6  (87/214)  0.001
Risk factors
Diabetes  33.1  (683/2062)  32.7  (608/1858)  36.8  (75/204)  0.241
Previous history
Stroke  12.0  (246/2055)  11.6  (216/1855)  15.0  (30/200)  0.169
PAD 16.1  (323/2012)  13.5  (245/1813)  39.2  (78/199)  <0.001
CAD 43.8  (900/2054)  42.3  (783/1852)  57.9  (117/202)  <0.001
PCI 23.1  (472/2047) 22.7  (419/1845)  26.2  (53/202)  0.254
CABG 17.7  (367/2070)  16.5  (307/1866)  29.4  (60/204)  <0.001
CKD 37.5  (767/2043)  36.9  (679/1842)  43.8  (88/201)  0.056
COPD 22.0  (454/2065)  21.7  (404/1862)  24.6  (50/203)  0.328
Previous ECG
Atrial  fibrillation 25.4  (512/2013)  25.3  (460/1817)  26.5  (52/196)  0.928
Pacemaker/CRT 7.1  (142/2013) 7.0  (128/1817)  7.1  (14/196)
Clinical status
Class  I-II  31.9  (631/1981)  32.7  (581/1778)  24.6  (50/203)  0.043
Class III-IV  68.1  (1350/1981)  67.3  (1197/1778)  75.4  (153/203)
EuroS-II 4.3  (2.5-7.1)  4.3  (2.5-7.0)  4.8  (2.9-7.9)  0.058
STS mortality  4.7  (3.0-7.1)  4.7  (3.0-7.1)  4.4  (2.9-6.9)  0.475
Baseline echocardiography
LVEF<50%  27.8  (538/1934)  27.3  (474/1736)  32.3  (64/198)  0.154
Mean baseline  gradient,  mmHg  49.4±16.1  49.6±16.3  48.6±14.8  0.461
Aortic valve  area,  cm2 0.64±.0.20  0.64±0.21  0.66±0.21  0.101
TAVI indication
AS  93.2  (2190/2347)  93.5  (1993/2131)  91.6  (196/214)  0.133
Aortic disease  2.3  (53/2347)  2.1  (44/2131)  4.2  (9/214)
Prosthesis  dysfunction  4.4  (104/2347)  4.4  (94/2131)  4.2  (9/214)
Surgical  risk
High  risk  49.7  (1167/2346)  50.3  (1072/2131)  44.4  (95/214) <0.001
Surgical contraindicationb 22.0  (517/2346)  20.6  (439/2131)  36.4  (78/214)
Other non-specified  28.3  (664/2346)  29.1  (620/2131)  19.1  (41/214)
Bridge balloon  aortic  valvuloplasty  2.9  (57/1946)  2.7  (48/1749)  4.6  (9/196)  0.174
CABG: coronary artery bypass graft; CAD: coronary artery disease; CKD: chronic kidney disease; COPD: chronic obstructive lung disease;
CRT: cardiac resynchronization therapy; EuroS-II: EuroScore II; LVEF: left ventricular ejection fraction; non-TF: non- transfemoral;
PAD: peripheral artery disease; PCI: percutaneous coronary intervention; TAVI: transcatheter aortic valve implantation; STS: Society
of Thoracic Surgery; TF: transfemoral; TA: transapical.
a CKD, defined as glomerular filtration rate <60 mL/min/m2.









bypass surgery with patent thoracic artery, as per heart team disc
Note: Data are presented as mean ± standard deviation or n (%).
aged  20  and  96,  respectively.  The  median  EuroS-II  was  4.3%
(IQR  2.5-7.1)  and  the  STS  score  mortality  risk  was  4.7%  (IQR
3.0-7.1).  The  majority  of  patients  were  in  NYHA  functional
class  III  or  IV  (68.1%).  The  predominant  route  was  trans-
femoral  (90.9%).  Self-expandable  valves  (SEV),  particularly
Medtronic  CoreValve,  were  used  more  frequently  (69.1%),
while  the  remaining  30.9%  were  balloon-expandable  (BEV)
Edwards  Valves.  Procedural  characteristics  are  presented  in
Table  2.
Transapical  access  was  the  most  used  non-transfemoral






nderwent  to  non-TF  prosthesis  implantation  (9.1%)
ere  significantly  younger  (non-TF  79±7  vs.  TF  81±7  years,
<0.001),  had  a  lower  prevalence  of  females  (non-TF  40.6%
s.  TF  54.5%,  p=0.001)  and  showed  a  higher  prevalence
f  PAD  and  coronary  artery  disease  (CAD),  including  more
atients  that  had  previously  undergone  surgical  coronary
evascularization.  As  expected,  this  group  tended  to  have  a
igher  surgical  risk  profile,  with  an  EuroS-II  of  4.8%  (IQR  2.9-
.9)  (vs.  TF  4.3  [IQR  3.2-8.6],  p=0.058),  which  was  clearly
ignificant  when  considering  only  transapical  access  route
atients  (TA  5.2%  [3.2-8.6],  p=0.012).  Half  of  the  global
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Table  2  Procedural  characteristics  of  the  study  population  and  according  to  the  access  route.
Variable  All  (n=2346)  TF  (n=2131)  Non-TF  (n=214)  p  value  (TF  vs.  non-TF)
TAVI  route -  -  na
Transfemoral  90.9  (2131/2345)
Transapical  5.8  (137/2345)
Transaortic  2.0  (48/2345)
Transubclavian  0.9  (20/2345)
Transcaval  0.4  (9/2345)
Valve  type  <0.001
CoreValve 52.0  (1217/2341)  54.3  (1153/2125)  29.0  (62/214)
Edwards  valve 30.9  (723/2341)  27.7  (588/2125)  63.1  (135/214)
Other 17.1  (401/2341) 18.1  (384/2125) 7.9  (17/214)
SEV 69.1  (1618/2341) 72.3  (1537/2125) 36.9  (79/214) <0.001
BEV 30.9  (723/2341)  27.7  (588/2125)  63.1  (135/214)
Post-dilatation  20.5  (408/1986)  21.4  (383/1789)  12.8  (25/195)  0.001
Second prosthesis  2.2  (44/1986)  2.5  (44/1789)  0  0.001
Repeat procedure  1.3  (26/2056)  1.2  (23/1849)  1.5  (3/205)  0.739
















































BEV: balloon-expandable valve; SEV: self-expandable valve; TAVI:
Note: Data are presented as mean ± standard deviation or n (%).
ohort  was  considered  by  the  heart  team  as  presenting  high
urgical  risk  (49.7%).  In  the  non-TF  group,  when  compared
ith  the  TF  group,  a  significantly  higher  proportion  pre-
ented  a  surgical  contraindication  supporting  the  decision
non-TF  36.4%  vs.  TF  20.6%,  p<0.001).  In  this  particular
roup,  as  expected,  BEVs  were  more  frequently  implanted
BEV  63.1%  vs.  SEV  36.9%),  and  less  post-dilatation  was  used
non-TF  12.8%  vs.  TF  21.4%,  p=0.001).  There  was  also  less
f  a  need  for  a  second  prosthesis  during  an  index  procedure
non-TF  0  vs.  TF  2.5%,  p=0.001).
n-hospital  and  30-days  results
n-hospital  results  are  shown  in  Table  3.  The  median  dura-
ion  of  hospitalization  decreased  over  the  years  (2007-2014
edian  9  [IQR  7-14]  vs.  2015-2018  median  7  days  [IQR  5-11],
<0.001);  Figure  2),  without  significant  differences  accor-
ing  to  the  selected  route.
Based  on  the  VARC-2  criteria,  the  immediate  implant
uccess  was  globally  high  (90.1%),  with  numerically  better
esults  for  TF  compared  to  a  non-TF  approach,  although
he  difference  was  not  significant  (TF  90.4%  vs.  non-TF
7.0%,  p=0.174).  There  was  a  low  rate  of  procedure-related
omplications  in  both  access  route  approaches.  TF  patients
ad  a  lower  prevalence  of  cardiac  tamponade  (TF  0.5%  vs.
on-TF  2.2%,  p<0.001),  perioperative  myocardial  infarction
TF  4.4%  vs.  non-TF  40.9%,  p<0.001)  and  Acute  Kidney  Injury
etwork  stage  2 or  3  (TF  3.9%  vs.  non-TF  6.9%  vs.  p<0.001).
 non-TF  approach,  particularly  transapical  and  transaortic,
as  associated  with  a  higher  occurrence  of  life-threatening
nd  major  bleeding,  and  also  major  vascular  complications
non-TF  7.3%  vs.  TF  6.3%,  p=0.001).  Stroke  occurred  in  4.6%
f  our  cohort,  mainly  non-disabling  (55%,  48/88),  and  the
revalence  of  TIA  was  very  low  (1.8%).
Globally,  moderate  or  severe  aortic  valve  regurgitation
ccurred  in  7.4%  of  patients,  without  significant  differen-




igure  2  Median  duration  of  hospitalization  for  the  global
ohort  according  to  the  year  strata  2007-2014  and  2015-2018
p<0.001  for  comparison).
equired  a  definitive  pacemaker  during  follow-up,  with  a
umerically  lower  rate  in  the  non-TF  group  (non-TF  15.0%
s.  TF  19.5%,  p=0.153).
Overall,  30-day  mortality  was  4.8%,  and  the  combined
afety  endpoint  occurred  in  85.0%  of  patients.  Both  end-
oints  were  significantly  better  for  the  TF  group,  with  a
ower  30-day  mortality  rate  (TF  4.3%  vs.  non-TF  10.1%,
=0.001)  and  higher  30-day  safety  endpoint  (TF  86.4%  vs.
on-TF  72.6%,  p<0.001).  It  is  interesting  to  note  the  timeline
tratification  curve  effect  in  Figure  3,  showing  the  evolution
f  30-day  mortality  incidence,  with  a  significant  reduction
ince  2011,  from  14.1%  to  less  than  4%  in  more  recent  years.ollow-up  and  mortality
he  median  clinical  follow-up  duration  was  259  (IQR  96-
16)  days,  with  an  accumulated  mortality  rate  of  14.0%.
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Table  3  In-hospital  and  follow-up  results  of  the  study  population  and  according  to  the  access  route.
Variable  All  (n=2346)  TF  (n=2131)  Non-TF  (n=214)  p  value  (TF  vs.  non-TF)
In-hospital  days 8  (6-12) 8  (6-12)  8  (6-11)  0.425
Immediate  implant  success  90.1  (1545/1714)  90.4  (1395/1543)  87.0  (147/169)  0.174
30-day safety  85.0  (1468/1727)  86.4  (1339/1550)  72.6  (127/175)  <0.001
30-day mortality  4.8  (110/2297)  4.3  (89/2087)  10.1  (21/208)  0.001
Procedure-related  complications
Coronary  obstruction  1.8  (14/772)  1.9  (14/738)  0  1.0
ECC support  1.3  (12/954)  1.2  (11/909)  0.5  (1/177)  0.442
Tamponade  1.0  (8/775)  0.5  (4/740)  2.2  (4/177)  <0.001
ViV 1.1 (8/725)  1.2  (8/690)  0  1.0
Conversion  to  surgery 0.4  (4/954) 0.3  (3/909) 0.5  (1/177) 0.176
In-hospital  complications
Stroke  4.6  (88/1893)  4.7  (81/1714)  4.0  (7/177)  0.916
Disabling 2.1  (40/1893)  2.1  (36/1714)  2.3  (4/177)  0.777
Non disabling  2.5  (48/1893)  2.6  (45/1714)  1.7  (3/177)
TIA 1.8  (35/1937)  1.8  (32/1757)  1.7  (3/178)  0.916
AKIN
AKIN stage  2 2.1  (40/1892) 2.0  (35/1717)  2.9  (5/173)  <0.001
AKIN stage  3 2.1  (39/1892) 1.9  (32/1717) 4.0  (7/173)
Pacemaker  requirement  19.0  (374/1964)  19.5  (343/1762)  15.0  (30/200)  0.153
Vascular complication
Major  6.8  (120/1766) 6.3  (110/1741) 7.3  (13/177)  0.001
Minor 16.5  (291/1766) 18.1  (315/1741) 6.2  (11/177)
Bleeding
Life-threatening  4.6  (94/2054)  4.1  (77/1861)  8.9  (17/191)  <0.001
Major 8.7  (179/2054)  7.4  (138/1861)  21.5  (41/191)
Minor 13.6  (279/2054)  14.0  (261/1861)  9.4  (18/191)
AMI
Perioperative  7.5  (145/1945)  4.4  (78/1779)  40.9  (67/164)  <0.001
NYHA on  follow-up
Class  I-II  94.3  (1201/1274)  94.3  (1074/1139)  93.9  (125/133)  0.133
Class III-IV  5.7  (73/1274)  5.7  (65/1139)  6.1  (8/133)
Moderate-severe  AR  7.4  (82/1114)  8.6  (77/897)  6.9  (9/131)  0.347
Prosthesis dysfunction  10.1(112/1114)  9.8  (88/897)  7.2  (10/137)  0.508
1-year rehospitalization  9.6  (98/1017)  9.0  (81/898)  14.3  (17/119)  0.071
1-year mortality  11.4  (194/1706)  10.5  (162/1541)  19.4  (32/165)  0.002
Overall mortality  14.0  (321/2300)  12.5  (261/2090)  28.8  (60/208)  <0.001











Heart Association; TIA: transient ischemic attack; ViV: valve-in-va
Note: Data are presented as mean ± standard deviation or n (%).
During  the  first  year  of  follow-up,  all-cause  mortality  rate
was  11.4%,  and  was  significantly  lower  for  TF  patients  (TF
10.5%  vs.  non-TF  19.4%,  p=0.002).  Clinically,  the  majority  of
patients  improved  their  functional  capacity,  with  a  reduc-
tion  in  the  percentage  of  patients  in  NYHA  class  III  and  IV  of
59.4%  and  8.8%  at  baseline  to  4.5%  and  1.3%  at  follow-up,
respectively  (p<0.05)  (Figure  4).Thirty-day  and  one-year  predictors  of  mortality
Following  adjustments  for  gender,  age,  previous  medi-





ndependent  predictors  of  30-day  all-cause  mortality  were
AD  (HR  2.24,  CI  95%  1.41-3.53,  p<0.001),  previous  PCI  (HR
.68,  CI  95%  1.07-2.63,  p=0.024),  LV  dysfunction  (LVEF<50%:
R  1.67,  CI  95%  1.07-2.63,  p=0.021)  and  a worse  functional
tatus  at  baseline  (NYHA  class  III-IV:  HR  1.98,  95%  CI  1.13-
.47,  p=0.017)  (Table  4).  At  one-year  follow-up,  as  shown  in
able  5, predictors  of  mortality  were  NYHA  class  III-IV  (HR
.11,  95%  CI  1.06-4.16),  non-transfemoral  route  (HR  1.76,
5%  CI  1.01-3.09,  p=0.046),  occurrence  of  life-threatening
leeding  (HR  2.44,  95%  CI  1.09-5.47,  p=0.030).  There  was
lso  a  trend  with  regard  to  chronic  obstructive  pulmonary
isease  (HR  1.68,  95%  CI  0.97-2.93,  p=0.063).  Valve  type
id  not  influence  mortality.
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Since  its  introduction  in  Portugal  in  2007,  the  number  of  TAVI
procedures  has  grown  exponentially,18 similar  to  the  patternFigure  4  Comparison  between  New  York  Heart  Association  f
Kaplan-Meier  survival  analysis  of  the  first  year  of  follow-
p  also  shows  decreased  survival  of  patients  who  underwent
on-transfemoral  TAVI  (log-rank  p<0.001)  and  those  with  hig-
er  surgical  risk  (EuroS-II>5%)  (log-rank  p<0.001).  There  was
lso  a  trend  of  decreased  survival  in  older  patients  (log-rank
=0.053)  (Figure  5,  A-E).
s
c
onal  class  at  baseline  and  follow-up  (p<0.05  for  comparison).
iscussioneen  following  the  adoption  of  this  technology  in  Western
ountries.23
Short  and  long-term  clinical  impact  of  transcatheter  aortic  valve  implantation  713
Table  4  Predictors  of  30-day  mortality.
Variable  Univariate,  HR  (CI  95%)  p  value  Multivariate  analysis,  HR  (CI  95%)  p  value
PAD  2.447  (1.584-3.780)  <0.001  2.235  (1.414-3.534)  <0.001
Non transfemoral  route  2.178  (1.338-3.546)  0.002
PCI 1.957  (1.291-2.965)  0.002  1.677  (1.070-2.629)  0.024
LVEF<50% 1.881  (1.238-2.858)  0.003  1.667  (1.079-2.578)  0.021
NYHA III-IV  pre  procedure  1.851  (1.132-3.026)  0.014  1.982  (1.131-3.474)  0.017
CAD 1.500  (1.000-2.249)  0.050
Atrial fibrillation  1.237  (0.794-1.927)  0.346
Age 1.023  (0.994-1.054)  0.118
ViV 0.372  (0.092-1.506) 0.166
Other adjusted variables: Aortic valve area, mean gradient, coronary artery bypass graft, chronic obstructive lung disease, chronic kidney
disease, EuroS-II, Society of Thoracic Surgery mortality risk score, type of valve (self-expandable valve and balloon-expandable valve),
size of prosthesis, permanent pacemaker need, moderate or severe paravalvular aortic leak.
Abbreviations: CAD: coronary artery disease; CI: confidence interval; HR: hazard ratio; LVEF: left ventricular ejection fraction; NYHA:
New York Heart Association; PAD: peripheral artery disease; PCI: percutaneous coronary intervention; ViV: valve-in-valve.
Table  5  Predictors  of  1-year  mortality.
Variable  Univariate,  HR  (CI  95%)  p  value  Multivariate  analysis,  HR  (CI  95%)  p  value
Age  1.021  (1.000-1.043)  0.05
Non-TF route  1.675  (1.143-2.453)  0.008  1.769  (1.011-3.096)  0.046
NYHA III-IV  pre  procedure  2.051  (1.397-3.011)  <0.001  2.110  (1.068-4.169)  0.032
Atrial fibrillation  1.839  (1.344-2.516)  <0.001
ViV 0.734  (0.345-1.563)  0.423
LVEF<50%  1.208  (0.972-1.673)  0.255
CAD 1.005  (0.748-1.350)  0.976
COPD 1.665  (1.213-2.286)  0.002  1.688  (0.971-2.933)  0.063
PAD 1.387  (0.961-2.001)  0.081
EuroS-II 1.016  (0.992-1.039)  0.187
STS risk  score  mortality  1.041  (1.020-1.060)  <0.001
Permanent  pacemaker  1.147  (0.800-1.644)  0.454
Life-threatening  bleeding  2.848  (1.514-5.355)  0.001  2.443  (1.091-5.472)  0.030
AKIN>=stage  2  3.149  (1.746-5.681)  <0.001
Vascular  major  complication  2.083  (1.242-3.495)  0.005
Moderate-severe  AR  2.376  (1.312-4.301)  0.004
Other adjusted variables: Aortic valve area, mean gradient, coronary artery bypass graft, chronic obstructive lung disease, chronic kidney
disease, EuroS-II, Society of Thoracic Surgery mortality risk score, type of valve (self-expandable valve and balloon-expandable valve),
size of prosthesis, permanent pacemaker need, moderate or severe paravalvular aortic leak.












pulmonary disease; EuroS-II: EuroScore II; HR: hazard ratio; LVEF
New York Heart Association; PAD: peripheral artery disease; PCI: p
Improved  survival  rates  after  TAVI,  with  a  significant
decrease  in  periprocedural  mortality,  reflect  innovative
device  technology,  but  also  the  increased  use  of  transfemo-
ral  TAVI,  learning  curves  and  optimized  patient  selection.24
The  increasing  availability  of  smaller  delivery  systems  and
operator  experience  have  brought  about  an  increase  in  the
number  of  patients  treated  with  a  TF  approach,  and  appro-
ximately  90%  of  our  patients  were  effectively  treated  using
TF  access,  a  percentage  slightly  above  the  80%  reported  in
FRANCE  TAVI,  with  a  corresponding  decline  in  transapical
access.25 The  predominant  use  of  SEV  in  our  registry  may
have,  on  the  one  hand,  been  influenced  by  the  steady  rise
in  TF  TAVI,  and  on  the  other  according  to  their  availability
in  Portugal.  As  expected,  balloon-expandable  valves  (BEV)





 ventricular ejection fraction; Non-TF: non-transfemoral; NYHA:
aneous coronary intervention; STS: Society of Thoracic Surgeons.
s  noteworthy  to  mention  that  currently  there  is  not  enough
vidence  to  claim  the  superiority  of  one  device  over  the
ther.26 Valve  selection  should  be  tailored  according  to  the
atient’s  clinical  and  anatomical  characteristics,  which  is
tandard  of  practice  at  the  different  Portuguese  TAVI  cen-
ers.
Evidence  showing  that  ViV  procedures  for  prosthesis
ysfunction  have  favorable  outcomes14 also  contribu-
ed  to  the  increasing  number  of  these  procedures  in
ortugal.
Approximately  50%  of  patients  were  considered  high  risk
or  surgery  following  a  heart  team  assessment.  This  was  not
xclusively  defined  according  to  conventional  surgical  risk
cores,  in  fact,  in  our  cohort  the  mean  EuroS-II  was  in  the
ntermediate  strata.  Other  factors,  such  as  advanced  age,









igure  5  Cumulative  survival  curves  according  to  access  route
C), type  of  valve  (D),  age  strata  (E).  *p<0.05.
ssociated  comorbidities  and  frailty  were  determining  fac-
ors,  although  the  latter  has  not  yet  been  fully  reflected
n  the  registry.  Evidence  shows  that  decision  making  in  val-
ular  heart  disease  involves  a  complex  algorithm  to  define





 EuroS-II  strata  (B),  timeframes  in  years  of  national  experience
pecific  TAVI  risk  score,  suggesting  that  the  best  approach
hould  be  based  on  the  combination  of  the  existing  surgical
cores  together  with  frailty  parameters  and  the  presence  of
























































priate  candidates  for  TAVI  accurately,  with  the  main  goalShort  and  long-term  clinical  impact  of  transcatheter  aortic  
Our  analysis  revealed  an  incidence  of  stroke  after  TAVI
of  4.6%,  of  which  almost  half  were  disabling.  Although  this
result  is  below  the  incidence  of  stroke  reported  in  the  PART-
NER  cohorts  A  and  B  (5.5  and  6.7%  respectively),27,28 and
similar  to  the  incidence  of  peri-operative  stroke  following
surgical  AVR  in  elderly  patients,  which  ranges  from  3  to
7%,29 this  is  still  a  matter  of  concern  and  an  area  of  impro-
vement  that  needs  to  be  addressed.  Embolic  protection
devices  (EPD)  are  not  used  by  default  at  Portuguese  TAVI
centers,  however,  so  far,  although  published  results  show
that  EPD  may  help  reduce  the  volume  and  size  of  periproce-
dural  silent  ischemic  brain  lesions  identified  on  MRI,  it  did
not  reduce  the  incidence  of  new  lesions  and  clinically  sig-
nificant  neurological  events.30,31The  clinical  impact  of  EPD
needs  further  investigation  in  randomized  trials  prior  to  its
widespread  use.
The  pacemaker  implantation  rate  in  our  registry  was  19%
in  the  overall  cohort,  with  a  significant  difference  between
TF  19,5%  and  TA  10.7%  approach.  This  attributed  to  the  dif-
ferences  between  the  predominant  prosthesis  type  used  in
each  of  the  access  routes  cohorts,  SEV  and  BEV,  respecti-
vely.  A  recent  meta-analysis  of  different  registries  showed
pacemakers  were  a  requirement  in  8%  of  Sapien  TFs  and
22%  for  CoreValve,15 in  line  with  our  data,  but  higher  than
those  reported  in  the  PARTNER  trials,  probably  because  of
the  higher  anatomic  complexity  of  real-world  patients.
Our  registry  reported  an  overall  7.4%  incidence  of  mode-
rate  paravalvular  leak  (>=2),  which  is  similar  to  other
European  registries  and  explained  by  the  operator  learning
curves,  standardization  of  techniques  and  new  generation
devices  with  extended  sealing  skirts.32
Concerning  hard  outcomes,  in  the  PARTNER  study,  mor-
tality  was  3.4  and  5%  in  cohorts  A  and  B,  respectively.6,33
Different  registries  present  wide  variability  in  mortality
ranging  from  5.4  to  12.4%,  however,  they  compare  diffe-
rent  patients  risk  profiles,  types  of  prosthesis  and  access
routes.29,34--36 In  our  global  cohort,  30-day  mortality  has  been
decreasing  since  the  beginning  of  the  TAVI  program,  from
14.1%  in  2011  to  approximately  4%  in  the  last  3  years,  which
is  in  line  or  slightly  below  other  reported  registries.14,25 It  is
probably  attributable  to  the  fact  that  although  our  cohort
had  an  advanced  mean  age  of  81  years,  the  mean  risk  profile
was  intermediate.  There  is,  in  fact,  a  growing  body  of  evi-
dence  that  supports  the  extension  of  TAVI  to  increasingly
lower  risk  patients,  consistently  demonstrating  its  nonin-
feriority  in  comparison  with  conventional  surgery.8,11 It  is
also  important  to  highlight  that  the  low  mortality  of  our
cohort  evidences  that  most  of  the  fatalities  were  unrelated
to  periprocedural  complications,  which  had  low  prevalence.
A  major  conclusion  from  these  data  is  that  our  focus  should
be  on  better  prediction  of  risks  and  benefits  of  the  procedure
and  appropriate  patient  selection.
Regarding  the  non-TF  approach,  and  particularly  the  TA,
when  comparing  with  TF  route,  the  former  was  associa-
ted  with  a  lower  30-day  safety  composite  outcome  and
higher  mortality  in  our  registry,  similar  to  what  has  been
reported  in  other  studies.33,37--39 The  explanation  is  multi-
factorial,  but  clearly  TA  patients  had  increased  prevalence
of  significant  co-morbidities  and  a  higher  risk  profile.  A  sig-
nificant  contribution  might  be  derived  from  the  increased
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nd  major  bleeding,  perioperative  myocardial  infarction  and
ardiac  tamponade.
Based  on  VARC  2  criteria,  the  predictors  for  30-day
ll-cause  mortality  were  PAD,  significant  CAD  with  pre-
ious  PCI,  depressed  left  ventricular  ejection  fraction  (LVEF)
nd  an  advanced  heart  failure  (HF)  clinical  status.  Bue-
lesfeld  et  al.  showed  the  patient’s  baseline  functional
tate  to  be  an  independent  predictor  of  hospital  mortality40
nd  the  Italian  registry  indicated  that  an  ejection  fraction
nder  40%,  diabetes,  prior  valvuloplasty  and  procedure-
elated  complications  were  associated  with  worse  short
erm  prognosis.29 The  Ibero-American  registry  also  under-
ined  the  importance  of  post-TAVI  complications  and  logistic
uroS-II  as  predictors  of  mortality  at  30  days.16 Also,  in  a
ecent  meta-analysis  stage>=2  AKI  was  a  strong  predictor
or  30-day  mortality,  although  interestingly  many  patients
aw  an  improvement  in  renal  function  after  TAVI  rather  than
idney  injury  due  to  renal  decongestion  and  increased  per-
usion.  Preprocedural  pro-brain  natriuretic  peptide  levels
ere  also  a  strong  predictor  of  30-day  and  midterm  mor-
ality.  This  is  believed  to  be  related  to  advanced  HF  with
ystolic  and  diastolic  dysfunction.  Likewise,  baseline  clinical
tatus,  represented  by  prior  hospitalizations  and  preproce-
ural  LVEF<=30%,  had  a  significant  impact  on  short  term
ortality.41
As  independent  predictors  of  one-year  all-cause  mor-
ality  we  identified  patient  characteristics  before  the
rocedure,  such  as  pre-procedural  NYHA  class  III/IV  and
hronic  obstructive  pulmonary  disease,  and  procedural  fac-
ors  such  as  the  non-NF  access  route,  which  may  be  a
urrogate  for  significant  PAD.  These  results  are  corrobo-
ated  by  other  registries  and  trials,  showing  also  that
ome  comorbidities  are  related  to  worse  long-term  pro-
nosis,  such  as  advanced  age,17 frailty,35 male  gender,
nd-stage  renal  disease,34 porcelain  aorta,35 low  gradient
ortic  stenosis,42 reduced  LVEF,17 NYHA  class,36 mitral
nsufficiency  grade>=2+,42 residual  postintervention  aor-
ic  regurgitation,6 intraprocedural  conversion  to  surgery,
eri-intervention  stroke,39 or  postintervention  pulmonary
mbolism.42
In  our  registry  there  was  a sub-optimal  percentage  of
atients  lost  to  follow-up  at  one-year  (22%),  although  accep-
able  when  compared  to  other  observational  studies.43,44,45
his  can  be  explained  by  the  nature  of  this  prospective
ationwide  real-world  registry  that  involves  participating
enters  with  various  differences  relating  to  the  volume  of
rocedures,  follow-up  approach  and  data  registration.  Also,
ompared  to  other  European  countries,  the  small  number  of
.346 to  0.7  TAVI  centers  per  million  inhabitants  in  the  regis-
ry  history,  can  limit  patient  accessibility  to  those  hospital
enters  because  of  distance,  which  is  a known  predictor  of
oss  to  follow-up.47 It  is  worth  mentioning  that  an  automa-
ic  registration  of  a  patient’s  vital  status  in  the  RNCI-VaP
ould  be  an  effective  way  of  strengthening  the  quality  and
ompleteness  of  data  in  the  future.
Despite  the  acknowledged  potential  bias,  the  findings
rom  this  landmark  study  should  help  us  to  select  appro-f  referring  patients  in  whom  treatment  benefit  outweighs
he  risk,  thus  improving  clinical  benefit  and  avoiding  futility.




























































n  high  risk  patients  with  several  comorbidities,  health-  rela-
ed  improvements  in  quality  of  life  and  reduced  congestive
F  hospitalizations  should  be  taken  in  account.
tudy limitations
he  data  from  the  RNCI-VaP  registry  is  self-reported  and
onsequently  subject  to  inclusion  bias.  Nevertheless,  this
egistry  is  representative  of  the  current  standards  of  prac-
ice  in  Portugal,  because  it  obtained  data  on  96.5%  of  the
otal  number  of  implanted  valves.
For  some  relevant  variables  we  could  not  obtain  data
rom  all  patients,  which  is  a  limitation  inherent  to  the
haracteristics  of  a  national  registry  that  depends  on  the
oluntary  participation  of  the  investigators,  potentially
ausing  selection  bias.  Events  were  reported  by  the  investi-
ators  and  were  not  independently  reviewed,  so  we  cannot
ule  out  the  possibility  of  under  or  over  reporting  of  events.
lso,  the  RNCI-VaP  does  not  currently  have  either  internal  or
xternal  auditing.  As  such,  definitive  conclusions  regarding
ause  and  effect  cannot  be  drawn  from  this  study.
Although  we  acknowledge  these  limitations,  the  investi-
ators  of  the  RNCI-VaP  consider  this  registry  to  be  essential
o  ensure  the  safe  and  successful  clinical  applicability  of
he  constantly  evolving  transcatheter  aortic  valve  techno-
ogy  in  Portugal.  This  paper  includes  the  first  published  data
n  patients  treated  with  TAVI  in  Portugal.  It  is  noteworthy
hat  the  success  and  complication  rates  were  similar  to  those
eported  by  other  European  countries’  registries.32
onclusions
he  RNCI-VaP  shows  that  TAVI  has  been  implemented  with
reat  success  in  Portugal.  In  this  real-world  all-comers
ll-centers  registry  of  patients  who  underwent  TAVI  (both
onventional  and  ViV),  the  procedure  was  safe  and  effec-
ive.  Characteristics  related  to  the  access  route,  patient
omorbidities  and  baseline  clinical  status  adversely  affec-
ed  long-term  prognosis  and  should  therefore  be  taken  in
onsideration  when  selecting  patients  for  the  procedure.
The  systematic  assessment  and  reporting  of  patients  who
nderwent  TAVI  in  Portugal  is  of  paramount  importance,  eli-
iting  a  pragmatic  assessment  of  TAVI  results  in  the  different
enters  and  stimulating  scientific  multicentric  production.
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